Publisher
Springer Science and Business Media LLC
Subject
Management of Technology and Innovation,Health Policy,Issues, ethics and legal aspects,Health (social science)
Reference57 articles.
1. Alexander, G. C., Emerson, S., & Kesselheim, A. S. (2021a). Evaluation of Aducanumab for Alzheimer disease: Scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA, 325(17), 1717–1718. https://doi.org/10.1001/jama.2021.3854
2. Alexander, G. C., Knopman, D. S., Emerson, S. S., Ovbiagele, B., Kryscio, R. J., Perlmutter, J. S., & Kesselheim, A. S. (2021b). Revisiting FDA approval of Aducanumab. The New England Journal of Medicine, 385(9), 769–771. https://doi.org/10.1056/NEJMp2110468
3. Alzforum. (2021). Solanezumab. Retrieved May 2022, from https://www.alzforum.org/therapeutics/solanezumab
4. Association, A. (2021). 2021 Alzheimer’s disease facts and figures. Alzheimer’s and Dementia, 17(3), 327–406. https://doi.org/10.1002/alz.12328
5. Bik, E. (2021). Cassava Sciences: Of stocks and blots. Retrieved May 2022, from https://scienceintegritydigest.com/2021/08/27/cassava-sciences-of-stocks-and-blots/
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献